Jonathan L Kaufman

33PUBLICATIONS
123CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyInnate immunityTe mātauranga pūkaha o te Māori (Māori engineering)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jan 21, 2026
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Melissa Alsina, Nina Shah, Sundar Jagannath

|May 15, 2025
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.

Marc S Raab, Yael C Cohen, Fredrik Schjesvold

|Mar 16, 2025
BCL2 inhibition for multiple myeloma and AL amyloidosis.

Lorenzo Cani, Vikas A Gupta, Jonathan L Kaufman

|Feb 06, 2025
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma.

Sayalee V Potdar, Shivani Kapadia, Maryam I Azeem

|Jan 02, 2025
Solvitur ambulando.

Jonathan L Kaufman

|Dec 04, 2024
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.

Dan T Vogl, Shebli Atrash, Sarah A Holstein

Pageof 6

Frequent Collaborators

12 joint publications

Ajay Nooka

12 joint publications

Craig C Hofmeister

9 joint publications

Madhav V Dhodapkar

6 joint publications

Sagar Lonial